ELTX (STOCKS)
Elicio Therapeutics, Inc. Common Stock
$3.101200
+0.041200 (+1.35%)
Prev close: $3.060000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Robert T. Connelly
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $79.09M
- Employees
- 26
- P/E (TTM)
- -1.31
- P/B (TTM)
- -39.69
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Costs And Expenses | $37.58M |
| Nonoperating Income/Loss | -$2.61M |
| Research and Development | $23.88M |
| Operating Income/Loss | -$37.58M |
| Income/Loss From Continuing Operations After Tax | -$40.19M |
| Income/Loss From Continuing Operations Before Tax | -$39.91M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$40.19M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$40.19M |
| Net Income/Loss Available To Common Stockholders, Basic | -$40.19M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.40 |
| Diluted Earnings Per Share | -$2.40 |
| Basic Average Shares | 51,028,531 |
| Diluted Average Shares | 51,028,531 |
| Assets | $22.69M |
| Current Assets | $16.20M |
| Noncurrent Assets | $6.49M |
| Fixed Assets | $249.00K |
| Other Non-current Assets | $6.24M |
| Liabilities | $24.13M |
| Current Liabilities | $7.23M |
| Accounts Payable | $272.00K |
| Wages | $833.00K |
| Other Current Liabilities | $6.12M |
| Noncurrent Liabilities | $16.90M |
| Equity | -$1.44M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$1.44M |
| Liabilities And Equity | $22.69M |
| Net Cash Flow From Operating Activities | -$38.48M |
| Net Cash Flow From Operating Activities, Continuing | -$38.48M |
| Net Cash Flow From Investing Activities | $3.84M |
| Net Cash Flow From Investing Activities, Continuing | $3.81M |
| Net Cash Flow From Financing Activities | $34.39M |
| Net Cash Flow From Financing Activities, Continuing | $34.39M |
| Exchange Gains/Losses | $22.00K |
| Net Cash Flow | -$199.00K |
| Net Cash Flow, Continuing | -$221.00K |
| Comprehensive Income/Loss | -$40.24M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$40.16M |
| Other Comprehensive Income/Loss | -$29.68M |